Bourgeon Capital Management LLC reduced its holdings in Chemours Co (NYSE:CC) by 13.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,350 shares of the specialty chemicals company’s stock after selling 2,250 shares during the quarter. Bourgeon Capital Management LLC’s holdings in Chemours were worth $214,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Investors Research Corp boosted its holdings in shares of Chemours by 148.1% in the 2nd quarter. Investors Research Corp now owns 1,206 shares of the specialty chemicals company’s stock worth $29,000 after acquiring an additional 720 shares in the last quarter. Point72 Hong Kong Ltd acquired a new position in shares of Chemours in the 2nd quarter worth approximately $29,000. Parallel Advisors LLC boosted its holdings in shares of Chemours by 479.4% in the 3rd quarter. Parallel Advisors LLC now owns 2,312 shares of the specialty chemicals company’s stock worth $35,000 after acquiring an additional 1,913 shares in the last quarter. Quadrant Capital Group LLC boosted its holdings in shares of Chemours by 423.4% in the 3rd quarter. Quadrant Capital Group LLC now owns 2,727 shares of the specialty chemicals company’s stock worth $36,000 after acquiring an additional 2,206 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. boosted its holdings in shares of Chemours by 41.7% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 3,782 shares of the specialty chemicals company’s stock worth $56,000 after acquiring an additional 1,113 shares in the last quarter. 79.88% of the stock is currently owned by institutional investors and hedge funds.

NYSE:CC traded up $0.04 during trading hours on Friday, hitting $19.69. 1,887,698 shares of the stock were exchanged, compared to its average volume of 2,583,418. The company’s 50 day moving average is $15.53 and its two-hundred day moving average is $19.91. Chemours Co has a twelve month low of $11.71 and a twelve month high of $41.60. The company has a quick ratio of 1.09, a current ratio of 1.72 and a debt-to-equity ratio of 5.05. The company has a market capitalization of $3.23 billion, a P/E ratio of 3.47, a price-to-earnings-growth ratio of 0.51 and a beta of 2.57.

Chemours (NYSE:CC) last posted its quarterly earnings data on Monday, November 4th. The specialty chemicals company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.03. Chemours had a return on equity of 58.38% and a net margin of 7.24%. The firm had revenue of $1.39 billion for the quarter, compared to the consensus estimate of $1.40 billion. During the same quarter in the prior year, the business earned $1.49 EPS. The business’s revenue for the quarter was down 14.6% compared to the same quarter last year. On average, equities research analysts expect that Chemours Co will post 2.44 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, December 16th. Stockholders of record on Friday, November 15th will be paid a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a dividend yield of 5.08%. The ex-dividend date of this dividend is Thursday, November 14th. Chemours’s dividend payout ratio (DPR) is currently 17.64%.

CC has been the topic of several recent analyst reports. Citigroup boosted their target price on Chemours from $14.00 to $21.00 and gave the stock a “neutral” rating in a report on Wednesday. SunTrust Banks boosted their target price on Chemours to $20.00 and gave the stock a “hold” rating in a report on Wednesday. Royal Bank of Canada downgraded Chemours from an “outperform” rating to a “sector perform” rating and reduced their price objective for the stock from $32.00 to $16.00 in a report on Friday, August 9th. ValuEngine downgraded Chemours from a “hold” rating to a “sell” rating in a report on Friday, November 1st. Finally, Susquehanna Bancshares raised Chemours from a “neutral” rating to a “positive” rating and reduced their price objective for the stock from $37.00 to $18.00 in a report on Tuesday, August 20th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and six have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $27.14.

In related news, COO Mark Newman purchased 20,000 shares of the business’s stock in a transaction dated Wednesday, September 11th. The shares were bought at an average price of $16.42 per share, with a total value of $328,400.00. Following the purchase, the chief operating officer now directly owns 114,261 shares in the company, valued at approximately $1,876,165.62. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 2.34% of the company’s stock.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment manufactures and sells titanium dioxide under the Ti-Pure and BaiMax brands for various applications in architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride window profiles, laminate papers used for furniture and building materials, and coated papers and paperboards used for packaging.

Featured Story: Bid-Ask Spread

Institutional Ownership by Quarter for Chemours (NYSE:CC)

Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.